Live Breaking News & Updates on Company Global Phase

Stay updated with breaking news from Company global phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and

Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical TrialPositive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial with Suprachoroidal Administration Presented at AAO 2023Preliminary Data from Phase 1 Trial in. ....

United States , Los Pinos , J Jill Hopkins , Mark Plavsic , Technology Officer , Suprachoroidal Administration , Novartis Company , Oncology Division , Company Phase , Aura Biosciences Inc , Exchange Commission , Exploratory Development At Novartis , Company Global Phase , Under Special Protocol Assessment , Compass Phase , Clinical Efficacy Updates , Early Stage Choroidal Melanoma , Ongoing Phase , Suprachoroidal Administration Presented , Bladder Cancer , First Patient Utilizing , Single Dose , Light Activation Demonstrated , Clinical Complete , Gross Proceeds , Underwritten Public ,

Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Received FDA Agreement Under Special Protocol Assessment for the CoMpass Phase 3 Clinical Trial

Positive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing. ....

United States , Mark Plavsic , Los Pinos , J Jill Hopkins , Technology Officer , Company Phase , Exchange Commission , Exploratory Development At Novartis , Novartis Company , Aura Biosciences Inc , Oncology Division , Company Global Phase , Aura Biosciences , Elisabet De Los Pinos , Chief Executive Officer , Compass Phase , Fast Track Designation , Gross Proceeds , Chief Medical Officer , Senior Vice President , Global Head , Exploratory Development , Gyroscope Therapeutics , Chief Technology , Chief Technology Officer , Fate Therapeutics ,